Valneva

Crucell Sweden is a biotechnology company that specializes in the development, manufacturing, and distribution of vaccines. It offers contract manufacturing services to vaccine companies both in Sweden and internationally. The company is involved in producing biological bulk materials and active pharmaceutical ingredients (API), as well as finished vaccine products for clinical trials and market supply. Additionally, Crucell Sweden focuses on developing antibodies aimed at preventing and treating infectious diseases, contributing to public health efforts through innovative vaccine solutions.

BliNK Biomedical is a biotechnology company focused on discovery and development of monoclonal antibody therapeutics, with an emphasis on immuno-oncology and cancer. It uses a B-cell technology platform to select and isolate antibody-producing cells from multiple species, including humans, mice, rabbits, and dogs, enabling deep mining for difficult targets and the identification of novel antibodies. Its programs aim to create first- or best-in-class antibody-based therapies, including lead candidates that target immune checkpoints to reprogram the tumor immune environment and render cancers susceptible to the body's immune response. The company was founded in 2014 and is based in Lyon, France.